The FDA yesterday approved an injectable form of PrEP. The medication can be administered every two months to help prevent someone from acquiring HIV.
As previously reported by Queerty, ViiV Healthcare, which is majority-owned by GlaxoSmithKline, has developed the injectable PrEP treatment called cabotegravir.
It will be marketed under the brand name Apretude.Anyone wanting to take Apretude must start by having two injections, one month apart.
They can then move to an injection every two months. Before having their first injection, they can take cabotegravir tablets (marketed as Vocabria) for four weeks.